Report Highlight and Description According to the latest report by IMARC Group, titled "Anti-Rheumatics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032," the global anti-rheumatics market size reached US$ 64.5 Billion in 2023. Rheumatoid arthritis is a chronic, autoimmune disease that affects the joints, articular tissues, and extra-articular organs. It is a progressive disorder that results in pain, inflammation, stiffness, and swelling of joints. Anti-rheumatics refer to drugs used to manage different symptoms of rheumatoid arthritis and modify the course of the disease. They can be administered subcutaneously (SC), orally, or intravenously (IV) into the body of the patient. Anti-rheumatics are also used to treat various types of cancer, and bowel, connective tissue, and autoimmune conditions, such as psoriatic arthritis, lupus, Sjogren syndrome (SS), systemic sclerosis ( SSc ), and systematic lupus erythematosus. Medical practitioners usually prescribe the drug to reduce pain, prevent bone deformity, reduce joint damage, preserve the structure and function of the joints, slow the progression of arthritis, and improve the person’s overall function. Request for a PDF sample of this report: https://www.imarcgroup.com/anti-rheumatics-market/requestsample